Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
NCT06943586
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Stroke
Transient Ischemic Attack (TIA)
Interventions
GENETIC:
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Sponsor
University of Alabama at Birmingham